<unk>  (rINN/USAN; codenamed SKI-606, marketed under the trade name Bosulif) is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia. Originally synthesized by Wyeth, it is being developed by Pfizer.
Bosutinib
Ibrutinib
Imatinib
Acalabrutinib
Ponatinib
Afatinib
Ceritinib
Ruxolitinib